*** *** ** 1 * (K=Clearance dialyzer, T= Time, V=Volume of distribation of urea) KT/V :

Relaterede dokumenter
Patientinddragelse i forskning. Lars Henrik Jensen Overlæge, ph.d., lektor

RIFLE KRITISKE PERSPEKTIVER. Marcela Carlsson Overlæge, ITA, OUH

Hvor skal man udføre akutmedicinsk forskning? Finn E. Nielsen Forskningslektor, overlæge, dr.med. MPA, MAppStat

Databaserne, indikatorer og forskning

X M Y. What is mediation? Mediation analysis an introduction. Definition

Hvilke faktorer understøtter eller hindre medicin adherence hos patienter med kronisk nyresygdom

FOLKESUNDHEDSPERSPEKTIV

Prioritering eller ej? Hvad er Konsekvensen? Jens Winther Jensen. Lægeforeningen

DDD is STILL better than VVI

Indhold 1. INDLEDNING...4

Teknologispredning i sundhedsvæsenet DK ITEK: Sundhedsteknologi som grundlag for samarbejde og forretningsudvikling

Basic statistics for experimental medical researchers

Key words: HSVE, Serological Diagnosis, ELISA

Generalized Probit Model in Design of Dose Finding Experiments. Yuehui Wu Valerii V. Fedorov RSU, GlaxoSmithKline, US

ReBUS (Rehabilitation, Bath, User Satisfaction)

OSAS CPAP behandling Hvor meget er nok? Ole Hilberg Lungemedicinsk afdeling Århus Universitetshospital

Quality indicators for clinical pharmacy services

Lovkrav vs. udvikling af sundhedsapps

Agenda. The need to embrace our complex health care system and learning to do so. Christian von Plessen Contributors to healthcare services in Denmark

Effekter og økonomiske konsekvenser ved afsaltet havvand til drikkevandsformål

Når behandlingen flytter hjem: muligheder og risici. Konsensusmøde om det borgernære sundhedsvæsen. Henning Boje Andersen

applies equally to HRT and tibolone this should be made clear by replacing HRT with HRT or tibolone in the tibolone SmPC.

BLÆREKRÆFT OG RYGERELATEREDE KOMORBIDITETER

Hvad er Asset Management

God, bedre, bedst. Hvad er optimal drikkevandskvalitet?

Health surveys. Supervision (much more) from the patients perspective. Charlotte Hjort Head of dep., MD, ph.d., MPG

Om risikofaktorer for tidlig genindlæggelse blandt 65+ årige.

A multimodel data assimilation framework for hydrology

Nationale kliniske retningslinjer Ernæringsterapi til underernærede patienter med KOL

Challenges for the Future Greater Helsinki - North-European Metropolis

Morbidity and Mortality

Laerdal Resuscitation User Network. Guideline 2015 og update om 10 steps to improve survival

HIV and Drug Prevention in Estonian Prisons

Selective Estrogen Receptor Modulatorer er farmaka, der kan binde sig til østrogen

N Engl J Med 2011;365:518-26

Sustainable investments an investment in the future Søren Larsen, Head of SRI. 28. september 2016

Epidemiology of Headache

Statistik for MPH: 7

Bedømmelse af klinisk retningslinje foretaget af Enhed for Sygeplejeforskning og Evidensbasering Titel (forfatter)

Sport for the elderly

Richter 2013 Presentation Mentor: Professor Evans Philosophy Department Taylor Henderson May 31, 2013

Integrated Coastal Zone Management and Europe

Uddannelse 2010 DMSc (Ph.d.) 2007 Speciallæge i Neurologi 1993 Læge

Forventer du at afslutte uddannelsen/har du afsluttet/ denne sommer?

Forventer du at afslutte uddannelsen/har du afsluttet/ denne sommer?

l i n d a b presentation CMD 07 Business area Ventilation

Anvendelse af Lægemiddelstatistikregistret til forskning: Fra opstart af evidensbaseret behandling til compliance og lægemiddelsikkerhed

Hvor mange har egentlig kræft?

Feedback Informed Treatment

ÆLDRE OG KRÆFT. Introduktion. Trine Lembrecht Jørgensen Læge, ph.d., post. doc. University of Southern Denmark. Odense University Hospital

Bedømmelse af klinisk retningslinje foretaget af Enhed for Sygeplejeforskning og Evidensbasering

Feedback Informed Treatment

Hvordan får vi bugt med det fedmefremmende samfund?

Er det usundt at træne meget? Kristian Overgaard Department of Public Health Sport Science Aarhus University

Using SL-RAT to Reduce SSOs

Kvant Eksamen December timer med hjælpemidler. 1 Hvad er en continuous variable? Giv 2 illustrationer.

IHI Triple Aim i Region Midtjylland

Feedback Informed Treatment

Sustainable use of pesticides on Danish golf courses

DoodleBUGS (Hands-on)

Multimorbiditet og geriatrisk screening

nyeste viden inden for plast

Rationel farmakoterpi

Børneortopædi CP-hoften på 20 minutter

The use of instrumented gait analysis in interdisciplinary interventions for children with cerebral palsy

Melbourne Mercer Global Pension Index

Håndtering af multisygdom i almen praksis

28 April 2003 Retrospective: Semicore Visit

Ansøgning om godkendelse af pesticider. Gælder fra 1. januar 2014.

Studieordning del 3,

Indlæg om Asset Management Lektor Lars Jenry Petersen Videncenter for Drift og Vedligehold

Ernæringsproblemer hos svækkede ældre. Anne Marie Beck, klinisk diætist, seniorforsker

MEDLEY CHALLENGE 2016/2017

Eksempler på anvendelse af registre og surveys til forskning om social ulighed i middellevetid og forventet levetid med godt helbred

USERTEC USER PRACTICES, TECHNOLOGIES AND RESIDENTIAL ENERGY CONSUMPTION

Appendices. Appendix 2: Questionnaire in StudSurvey. Appendix 3: Text presenting the electronic questionnaire. Appendix 4: Outputs from regressions

DANSK NEFROLOGISK SELSKAB

A Framework for Decentralized Decision-making in IVM

Er det forsvarligt at være alene hjemme efter dagkirurgi?

Bilag J - Beregning af forventet uheldstæthed på det tosporede vejnet i åbent land Andersen, Camilla Sloth

Brystkræftscreening og overdiagnostik hvordan forstår vi stigningen i incidens?

Syddansk Universitet. Notat om Diabetes i Danmark Juel, Knud. Publication date: Document Version Også kaldet Forlagets PDF. Link to publication

4. Oktober 2011 EWIS

Reviews ;

Manuel behandling for patienter med hofteartrose

Camilla van Deurs. Associate partner Arkitekt MAA PhD Lektor i Urban Design. Gehl Architects. Menneskevenlige byer er sunde byer!

BANGKOK FASE 2 - VALGFAG INFORMATION, VEJLEDNING OG DOKUMENTER

Novo Nordisk virksomhedscase. Martin Kristiansen

IP01: Permeable befæstelser

Personale mangel 3 mulige løsninger

Etablering af en ny database: Dansk Palliativ Database

Financing and procurement models for light rails in a new financial landscape

13 års forskel i Ålborg

Dansk nefrologisk selskab

Til 26. juni 2013 Formand for Sundheds- og Velfærdsudvalget Jesper Hammer Sundhedschef Lisbeth Pedersen. Kære Jesper og Lisbeth

Hjemmefødsler - en medicinsk teknologivurdering

Erektiv dysfunktion og ESWT

Remember the Ship, Additional Work

Registre og kvalitetsdatabaser - Big Data

IP01: Permeable befæstelser

Transkript:

60-66 /1385 /2 8 / *** *** ** 1 * *** - ** - *. - 85/5/16 : - 85/1/24 : : :... :. 200. 250..( 4 ).. t (K=Clearance dialyzer, T= Time, V=Volume of distribation of urea) KT/V : (Urea Reduction Ratio) URR 1/195±0/456 0/943±0/335 250 200. 60/178±10/74 250 53/3±13/6 200.(p<0/05) %25 :.. :.(1) 5 4 64 60.(3 2) :. 10 7 44 40 1 0811-8222401 : - : 60 E-mail: edu1374@yahoo.com

..(17-21). (23 22) KT/V (24)..(25).(26 11) (21 18 17)..(4-10) NCDS.(11) (National Cooperative Dialysis Study).(3). KT/V. KT/V KT/V urea...(14 13 12) URR URR (Urea Reduction Ratio).(15) KT/V 65 URR 1/2 KT/V (URR).(16).. 61

1385 /2 8 /. 4 ).( 50.. Daugirdas II.(28 27) (URR).. t. : 66/7 40 49 (%28/6) 54/8 60 (%28/6) :. : 3.. ().. 200 250. ) (. 62

250 200 URR :1 250 200 URR 00/0 0 9/5 4 25-34 7/1 3 11/9 5 35-44 19/0 8 40/5 17 45-54 38/1 16 21/4 9 55-64 35/7 15 16/7 7 65-75 URR=Urea Reduction Ratio. p<0/05 t - 61/9 55-64 (54 ) URR 16/6 KT/V.(1 ) 1/3-1/7 KT/V 45/2 (2 ) 0/9 1/2 1-3 61/9. 16/7 200 21/4 65 URR 250 200 KT/V :2 250 200 KT/V 23/8 10 38/1 16 0/3-0/8 50 21 45/2 19 0/9-1/2 21/4 9 11/9 5 1/3-1/7 4/8 2 4/8 2 1/8-5 KT/V: K=Clearance, T=Time, V=Volume of distribution urea.. p<0/05 t - 63

1385 /2 8 / (32) KT/V=1/2 0/1 (22) 5-7.(25 23 22) : 400 200 33.(25) 250. :. 200 0/943±0/335 KT/V. 250 1/195±0/456 53/30±13/61 200 URR t. 60/118±10/74 250 95. KT/V URR : 16/66 200 16/7 (M=0/49) 1/3 KT/V (M=53/3) 65-75 URR KT/V ) (30) (1/3 KT/V ) (29) (1/67 (0/9±0/26 ) (1/03±0/25 ) (20) (1/2 %80) (18) (1/2 %90) (19). kim 15-20 KT/V (24) 1/2..(31) KT/V 0/1 USRDS 64

: 1. Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Gutzwiller F, Zehnder CE. Estimating phosphate removal in hemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant. 2002; 17(6): 1038. 2. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolf RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002; 13: 1061-6. 3. Hakim RM. Assessing the adequacy of dialysis. Kidney Int. 1990; 37: 822-32. 4. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329: 1-6. 5. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis. 1994; 23: 272-82. 6. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity. N Engl J Med. 1991; 305: 1176-80. 7. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994; 23: 661-9. 8. Lowrie EG. Chronic dialysis treatment: clinical outcome and related processes of care. Am J Kidney Dis. 1994; 24: 255-66. 9. Gotch F, Levin NW, Port FK, Wolfe RA. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis. 1997; 30: 1-15. 10. Owen WF, Chertow G, Lazarus JM, Lowrie EG. The dose of hemodialysis: Mortality responses by race and gender. JAMA. 1998; 280: 1-6. 11. Sehgal AR, Dor A, Tsai AC. Morbidity and cost implication of inadequate hemodialysis. Am J Kidney. 2001; 37(6): 1223-31. 12. Hemodialysis adequacy work group. Dialysis outcomes quality initiative (DOQI). Am J Kidney Dis. 30(suppl2): 1997; 22-31. 13. Gotch FA, Sargent JA. A mechanistic analysis of the national cooperative dialysis study (NCDS). Kidney Int. 1985; 28: 526 34. 14. Held PJ, Port FK, Wolfe RA, Stannard DC. The dose of hemodialysis and patient mortality. Kidney Int. 1996; 50(2): 550 6. 15. U.s department of health and human services. Hemodialysis dose and adequacy. NIH Publication. No.03-4556 Septamber 2003. 16. Lindsay RM, Spanner E. Adequacy of hemodialysis in the elderly. Geriatr Nephrol Urol. 1997; 7(3): 147-56...17.20-25 :23 1381. 1387..18.52-7 :14 1383..1381 65

1385 /2 8 / ( )...19.40-6 :(41)13 1382. - 1379...20.82-7 :17 1380. -.1377...21.27-33 :(3)10 1382. 22. Cigarran S, Coronel F, Torrente J, Sevilla M. Risk of inadequate dialysis dose in hemodialysis patients with high Watson volume. Hemodialysis Int. 2004; 8(1): 84. 23. Hauk M, Kuhlmann MK, Riegel W, Kohler H. Invivo effects of dialysate flow rate on Kt/v in maintenance hemodialysis patients. Am J Kidney Dis. 2000; 35(1): 105-11. 24. Kim YO, Song WJ, Yoon SA, Shin MJ, Song HC, Kim YS, et al. The effect of increasing blood flow rate on dialysis adequacy in hemodialysis patients with low Kt/v. Hemodialysis Int. 2004; Vol 8. 85. 25. Daugirdas JT, Van Stone JC, Boag JT. Hemodialysis apparatus. In: Daugirdas JT, Blake PG, Ing TS (eds.). Handbook of dialysis. Philadelphia: Lippincott Williams & Wilkins Company; 3 th ed. 2001. p: 46-66..1377....26 27. Kovacic V. The assessment of hemodialysis technical efficacy. Official publication of the Indian. J Nephrol. 2004; 14(1): 1-9. 28. Kovacic V, Roguljic L, Jukic I. Comparision of methods for hemodialysis dose calculation. Dialysis & Transplantation. 2003; 32(4): 170-5. 29. Charra B, Calemard E, Ruffet M, Man NK. Survival as an index of adequacy of dialysis. Kidney Int. 1992; 41: 1286-91. 30. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Did. 1994; 23(2): 272-82. 31. Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Garbani E, Zehnder CE. Increasing blood flow increase kt/v and potassium removal but fails to improve phosphate removal. Clin Nephrol. 2003; 59(2): 130-6. 32. Bloembergen WE, Stannard DC, Port FK. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int. 1996; 50: 557-65. 66